Using flow cytometry, we found that the frequencies of tumor-associated CD4+ and CD8+ T cells and myeloid-derived immune subsets 48 h post-shIDO-ST treatment were comparable to HBSS (no-ST) and shScr-ST control groups (Figure 3A, Supplemental Figure S2A), suggesting that these populations are preserved in the absence of a cytotoxic neutrophil response [22]. This evidence concerns the gene CD4 and neoplasm.